As previously announced, TRUFORMA can be installed entirely remotely, which should help limit the impact of the COVID-19 pandemic on instrument installations.About Zomedica Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for dogs and cats by focusing on the unmet needs of clinical veterinarians. Readers are cautioned not to place undue reliance on forward-looking information.Investor Relations Contact: PCG Advisory Group Kirin Smith, COO firstname.lastname@example.org +1 646.863.6519, ANN ARBOR, Mich., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) announced today that its proxy solicitor, Alliance Advisors, mailed the following letter to selected shareholders in advance of its Annual and Special Virtual-Only Meeting of Shareholders to be held on September 25, 2020.Â Dear Zomedica Pharmaceuticals Corp. The Company also announced the resignation of Shameze Rampertab as Chief Financial Officer, effective August 14, 2020.Â Â Â Â Â Â Â Â Â Â Â Â Â Summary Second Quarter 2020 ResultsZomedica recorded net loss and comprehensive loss for the three and six months ended June 30, 2020 of $5,307,990, or $0.02 per share, and $7,758,607, or $0.05 per share, compared to a loss of $2,404,427, or $0.02 per share, and $14,081,337, or $0.13 per share, for the three and six months ended June 30, 2019.Research and development expense for the three months ended June 30, 2020 was $3,908,171 compared to $1,061,507 for the three months ended June 30, 2019, an increase of $ 2,846,664 or 268%.Â The increase primarily resulted from a milestone expense of $3,000,000 recognized in accordance with our development and supply agreement with Qorvo Biotechnologies, LLC. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. The By-law Amendments will cease to be effective if they are not ratified and confirmed by the shareholders at the Meeting.Â The By-law Amendments update and modernize the Corporations by-laws, and amendments include the following provisions: * To allow the Corporation to hold shareholder meetings by electronic means, to allow shareholders to participate in a meeting by electronic means, and to allow shareholders to vote at a meeting using electronic means, if the Corporation makes available a communications facility for that purpose; and, * To change the quorum at a meeting of shareholders to be two persons present and holding or representing by proxy not less than 25% of the outstanding common shares entitled to be voted at the meeting.The By-law Amendments currently are being filed on the Corporationâs SEDAR profile at www.sedar.com and on EDGAR at www.sec.gov. The Circular is being provided to shareholders pursuant to notice and access procedures under applicable securities laws that we are utilizing in connection with the meeting, and also may be accessed at the Companyâs profile on EDGAR in the United States at www.sec.gov and on SEDAR in Canada at www.SEDAR.com. Zomato raises $195 million in funding from 6 investors, valuation touches $3.6 billion Upon closing of the fundraise, Info Edge's shareholding in Zomato shall stand reduced to about 20.8 … Indian food delivery startup Zomato cuts 13% of workforce. The gross proceeds from this offering are approximately $20.0 million, before deducting placement agentâs fees and other estimated offering expenses payable by the Company, assuming none of the warrants sold in this offering are exercised for cash. Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (âZomedicaâ or âCompanyâ), a veterinary diagnostic company, today reported consolidated financial results for the first quarter ended March 31, 2020. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts; uncertainty as to our ability to supply equipment and assays in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of our obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR at www.sedar.com.
Seed Paper Packaging Wholesale, Greenply Industries Ltd Company Profile, Laneige Neo Cushion Matte Swatch, Microwave Convection With Trim Kit, Zwilling Professional S, Maximo Rialto Grand Polished Porcelain Tile, Msi Gf65 Ram Speed, Weber Zesty Lemon Seasoning Discontinued, Calasiao, Pangasinan Barangays,